Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2008-08-31 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Presentation - Update 29 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from September 2008 by Pharmaxis, focusing on their therapeutic products for respiratory diseases. It includes forward-looking statements, clinical trial phases, product pipelines, regulatory statuses, marketing applications, and market opportunities. The content is typical of an investor presentation, providing strategic, clinical, and regulatory information to investors rather than financial statements or regulatory filings. There is no indication that this is an annual report, earnings release, or regulatory filing. The presence of forward-looking statements and detailed product and clinical trial information aligns with the characteristics of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2008-08-31 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares acquired, the nature of the interest, and the date of change. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is short and focused solely on director share transactions, with no financial statements or other report content. Therefore, the correct classification is Director's Dealing (DIRS).
2008-08-26 English
12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectas 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 20 August 2008 from Pharmaxis Ltd announcing the conclusion of a 12-month Phase 3 clinical trial for Bronchitol. It discusses trial results, safety, and future marketing plans. There are no financial statements, regulatory filings, or detailed financial data. The content is a corporate announcement about clinical trial results and future intentions, not a financial report or regulatory filing. It is not an earnings release, annual report, or any other financial document type. The document fits best as a Regulatory Filing (RNS) because it is a general corporate announcement that does not fit other specific categories.
2008-08-19 English
Bronchitol Phase 3 Cystic Fibrosis Trial Closes Recruitment 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing the completion of recruitment for a Phase 3 clinical trial of Bronchitol by Pharmaxis. It provides details about the trial design, recruitment numbers, expected data availability, and regulatory designations but does not contain any financial statements, detailed financial analysis, or regulatory filings. It is a corporate announcement related to clinical trial progress rather than a financial report or regulatory filing. The document length is under 5,000 characters and is clearly a press release. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement or corporate update that does not fit other specific categories.
2008-08-17 English
Preliminary Final Report 42 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'ASX Preliminary final report – 30 June 2008' and references the year ended 30 June 2008, indicating it covers a full fiscal year. It includes detailed financial statements such as income statements, balance sheets, cash flow statements, and notes to the financial statements. The document also mentions it is lodged under ASX Listing Rule 4.3A, which relates to preliminary final reports. The text includes comprehensive financial data, operational commentary, audit status, and detailed financial results, consistent with a full annual report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2008
2008-08-12 English
Bronchitol Cystic Fibrosis Dose Trial Results Positive 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 12 August 2008 from Pharmaxis Ltd announcing positive results from a Phase II clinical trial of Bronchitol for cystic fibrosis. It contains detailed trial results, including primary and secondary endpoints, patient population, and dosage information. The document is a press release or media announcement rather than a formal regulatory filing or financial report. It does not contain financial statements, management discussion, or regulatory certifications. It is not an earnings release or investor presentation but rather a clinical trial result announcement. Given the content and format, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2008-08-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.